RxDoctor Payments Data

Corey Musselman, MD

Family Medicine · Cary, NCNPI 1497802193

Payments from drug & device makers

$11,528in general payments, 2019–2025

Across 758 payments — averaging $15.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • AstraZeneca$883
  • Boehringer Ingelheim$864
  • Takeda Pharmaceuticals U.S.A., Inc.$633
  • Amgen$618
  • plus $5K from 42 others

What the payments were for

  • Food & beverage$11,46699%
  • Education$621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,528 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$163,720
Medicare patients
429
Services billed
2,501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide166$225,933
JardianceEmpagliflozin73$101,432
EliquisApixaban49$51,146
FarxigaDapagliflozin Propanediol37$45,953
MounjaroTirzepatide32$33,702
RybelsusSemaglutide15$32,735
TrulicityDulaglutide18$21,630
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$14,152
Xigduo XrDapaglifloz Propaned/Metformin15$13,804
XareltoRivaroxaban11$13,127
Repatha SureclickEvolocumab12$10,730
VascepaIcosapent Ethyl17$9,437
Tresiba Flextouch U-200Insulin Degludec12$9,365
SynthroidLevothyroxine Sodium87$8,343
Advair HfaFluticasone Propion/Salmeterol12$7,688

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,146$258,668181 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$864$113,01296 claims
PfizerEliquis, Premarin, Abrysvo$404$62,39176 claims
Lilly USA, LLCMounjaro, Trulicity$334$55,33150 claims
AstraZenecaFarxiga$883$45,95337 claims
GSKTrelegy Ellipta$343$14,15215 claims
Johnson & JohnsonXarelto$419$13,12711 claims
AbbVieSynthroid$1,636$8,34387 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$38$4,028307 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Cary

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →